Versant Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRY
Versant Capital Management's SPRY Position: Q3 2026 in Review
Versant Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 113% in Q3 2026, buying an estimated $6.53K and bringing the position to 2,108 shares worth $9.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.
Versant Capital Management first reported a position in SPRY in Q1 2025 and has held it in 7 quarters since. The position peaked at $30K in Q4 2025. 191 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.
- Versant Capital Management held 2,108 shares of ARS Pharmaceuticals worth $9.08K as of Q3 2026.
- Versant Capital Management bought 1,117 ARS Pharmaceuticals shares in Q3 2026, an estimated $6.53K.
- ARS Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2294 holding.
- Versant Capital Management first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
- Versant Capital Management's ARS Pharmaceuticals position peaked at $30K in Q4 2025.
- 191 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.